Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: brightmindsbio.com
Date | Price Target | Rating | Analyst |
---|
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system ("CNS") clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas' engagement with Bright Minds as Chief Medical Officer has been terminated. "I'm thrilled
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment of Doug Williamson to the Company's Board of Directors (the "Board"). Dr. Williamson will serve on the Compensation, Nominating and Corporate Governance, and Audit Committees as an independent
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/ VANCOUVER, BC, Dec. 6, 2023 /CNW/ - Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company specializing in the development of novel treatments for neuropsychiatric disorders, epilepsy, and pain, is excited to announce a fully management-subscribed, non-brokered private placement. This placement involves up to 661,765 units of the Company (the "Units") at a price of $1.36 per Unit, aiming for aggregate gross proceeds of up to $900,000 (the "Offerin
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study -- Proof of Mechanism and target engagement in the brain was established using blood biomarkers and qEEG -- In qEEG, BMB-101 demonstrated robust increase in central delta power and robust reduction in central alpha and beta power in active group, as previously reported for Anti-Epileptic Drugs (AEDs) in healthy individuals -- Company to host
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study -- BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric diso
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the "Common Shares") on a five (5) to one (1) basis (the "Consolidation"). The Company's post-Consolidation Shares are expected to begin trading on the Canadian Securities Exchange and The NASDAQ Capital Market on July 14, 2023. The name of the Company and trading symbol will remain the same aft
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the "Common Shares") on a five (5) to one (1) basis (the "Consolidation"). The Consolidation has been approved by the Company's board of directors in accordance with the Articles of the Company. The Company currently has 18,860,359 Common Shares issued and outstanding. Following the completion of the Consolidation, the Company is expected to have
-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds -- VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the International Searching Authority reviewed its international pa
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Alex Vasilkevich, Bright Minds' Scientific Officer, will present at the 20th International Meeting of the International Society for Serotonin Research (ISSR). The ISSR, a nonprofit founded
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment to its board of directors (the "Board") of David Weiner, MD, as a non-executive director. The appointment is effective immediately. "I am delighted to welcome David to the Bright Minds Board. He
VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that it has received a letter (the "Deficiency Letter") from the Nasdaq Stock Market LLC ("NASDAQ") dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company's board of directors and audit committee, the Company no longer complies with NASDAQ's independent director and audit committee requirements as set forth in Listing Rule 5605. Listing Rule 5605(b)(1) states that the Company's board of directors must consist of a majority independent directors and Listing Rule 5605(c)(2) states that the
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
D - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
20-F - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."By Grant Stringer, Oregon Capital ChronicleA year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.To attract them, advocates say the industry needs to get the word out about its benefits."We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey,"
https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next month where an expert committee will examine the evidence behind the application.Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced on Monday that FDA's Psychopharmacologic Drugs Advisory Committee will meet on June 4 to review the results of its clinical trials for the psychedelic-assisted therapy.Not only will this be the first time in 25 years since FDA has reviewed a n
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). The agency has proposed both be listed as Schedule I substances under the Controlled Substances Act (CSA). If added to the Schedule I list, these compounds would be officially considered as having high abuse potential with no recognized medical use. The evaluation is being disputed by experts. Three formal requests for a hearing were submitted, prompting a reconsideration by the agency.
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley’s novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.) BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) Learn more. Utah Hospita
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated psilocybin analog targeting the adjunctive treatment of Major Depressive Disorder (MDD.) It makes the group of psychedelic-based treatments for mental health conditions that have in recent years received such status granted by the U.S. federal agency five therapies total: Cybin's, MindMed's (NASDAQ:MNMD) LSD-derived treatment for
https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/The Indiana legislature has sent a bill to the governor's desk that includes provisions to fund clinical research trials into psilocybin.The House and Senate both passed the underlying legislation on health care issues, which was amended to add the psychedelics language, last week.The reform provisions that lawmakers attached to the broader legislation were taken from a standalone measure from Sen. Ed Charbonneau (R) that cleared the Senate last month and then advanced through a House committee.Charbonneau said in a press release on Friday that the intent of the proposal is to provide funding
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.) With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing significant distress and impairment in social, occupational or other areas of functioning. A relatively common disorder, successful treatment of GAD remains inadequate, bringing on side effects and high costs. The new topline clinical outcomes correspond to a Phase 2 study assessing psilocybin thera
Welcome to Benzinga's psychedelics headlines roundup. This is our pick of must-read news items concerning the last few days of January and the first two weeks of February 2024. See previous edition: Anti-inflammatory Effects, Global Drug Survey, ‘Synthetic Surprise,’ UK’s Harm Reduction Hub And More Research Comparative Review On Efficacy, Safety, Pharmacokinetics and Binding Profile of Serotonergic Psychedelics by MindMed's (NASDAQ:MNMD) Swiss research collaborators (read.) Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions (read.) Indigenous ps
Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months A new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD and improved sexual function up to six months after they have been consumed. Believed to be the first scientific research into the effects of psychedelics and sex, the new findings combine responses from nearly 300 participants who reported overall improvements after a psychedelic experience. Keep reading. Groundbreaking: FDA Reviews MDMA Therapy For PTSD, Accepts New Drug Application The Food and Drug Administration (FDA) has recently accepted a New Drug Application (NDA) from Lyk